Genmab ditches drug candidate

The biotech firm genmab shelves cancer project which US J.P. Morgen predicted would have sales potential at USD 2bn per year.

Photo: Lars Møller / Genmab / PR

The Danish biotech firm Genmab has lost a potential blockbuster drug. Genmab has decided to ditch the drug candidate enapotamab vedotin for treating cancer, which the firm announces in a statement.

"We are committed to developing innovative antibody products for patients with cancer, however the data from the enapotamab vedotin expansion cohorts unfortunately does not support moving this product candidate forward," states CEO  Jan van de Winkel in the press announcement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs